+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Advanced Drug Delivery Systems Market - Growth, Trends, and Forecasts (2020-2025)

  • PDF Icon


  • 71 Pages
  • May 2020
  • Region: North America
  • Mordor Intelligence
  • ID: 4833420
North America drug delivery systems market is expected to register a CAGR of around 4.8 % during the forecast period. The factors that are driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.

The advanced drug delivery systems are more focused on the maintenance of bioavailability of drug as per patient requirement, as well as the rate of drug delivery. Genetic engineering led to the development of new strategies to deliver biotechnologically-derived protein, peptide drugs, and chemoimmunoconjugates. The advanced drugs and biologics have higher efficiency with a smaller dosage of the drug, and hence they have to be supported with advanced drug delivery systems to gain maximum efficacy from the drug. In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others.

Furthermore, increasing disease burden across the world, the proven efficacy of controlled-release drug delivery systems in addressing a wide range of diseases, and the growing R&D trends by both the innovators and the generic players for advanced drug delivery systems, are propelling the growth of the market. However, factors such as product recall of advanced drug delivery products and challenges in nanomedicine based drug delivery act as a major restraint to the market growth.

Key Market Trends

Injection-based Drug Delivery System dominates the North America Advanced Drug Delivery Systems Market

The technological advancement processes have resulted in the advent of improved and enhanced devices, as well as equipment that is tailor-made and specific to different categories of patient care. In addition, technological innovations, like dual-injectable drug delivery system, have further enhanced the method of drug delivery. They also offer many features and functions that improve usability, safety, efficacy, and compliance, as well as many other functions, such as connectivity and even diagnostics. With the advent of self-injection devices, like auto-injectors, pen-injectors, and needle-free injectors, the use of injectable drug delivery (IDD) has been made relatively easy, allowing patients to administer drugs at home without medical assistance. The increase in the number of diabetic patients has allowed the majority of the leading players in this market to launch devices for the administration of insulin, with the help of self-injection devices. Thus, the homecare settings contribute as the largest end users for injectable drug delivery systems.

Competitive Landscape

North America advanced drug delivery systems market is moderately competitive. Some of the major players in this market are 3M, Bayer, Pfizer Inc., etc. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of New Drugs and Biologics
4.2.2 Advancements in Understanding Human Biology and Diseases
4.2.3 Increased R&D Spending
4.3 Market Restraints
4.3.1 Product Recalls of Advanced Drug Delivery Products
4.3.2 Challenges in Nanomedicine-based Drug Delivery
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 Type
5.1.1 Oral Drug Delivery System
5.1.2 Injection-based Drug Delivery System
5.1.3 Inhalation/Pulmonary Drug Delivery System
5.1.4 Transdermal Drug Delivery System
5.1.5 Trans mucosal Drug Delivery System
5.1.6 Carrier-based Drug Delivery System
5.1.7 Other Types
5.2 Application
5.2.1 Cardiovascular Diseases
5.2.2 Oncology
5.2.3 Urology
5.2.4 Diabetes
5.2.5 CNS
5.2.6 Ophthalmology
5.2.7 Inflammatory Diseases
5.2.8 Infections
5.2.9 Other Applications
5.3 Technology
5.3.1 Prodrug
5.3.2 Implants and Intrauterine Devices
5.3.3 Targeted Drug Delivery
5.3.4 Polymeric Drug Delivery
5.3.5 Other Technologies
5.4 Geography
5.4.1 North America United States Canada Mexico
6.1 Company Profiles
6.1.1 3M
6.1.2 Aradigm Corporation
6.1.3 Amgen Inc
6.1.4 Astrazeneca PLC
6.1.5 Bayer Healthcare
6.1.6 Boston Scientific Corporation
6.1.7 Pfizer Inc
6.1.8 Merck & Co, Inc
6.1.9 Novartis AG
6.1.10 West Pharmaceutical Services, Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3M
  • Aradigm Corporation
  • Amgen Inc
  • Astrazeneca PLC
  • Bayer Healthcare
  • Boston Scientific Corporation
  • Pfizer Inc
  • Merck & Co, Inc
  • Novartis AG
  • West Pharmaceutical Services, Inc.